Impact of drug shortages on patient care: when drugs aren't available

Imagine walking into a pharmacy or hospital expecting your regular medication, only to be told it’s gone. Not just out of stock for a few days, but missing entirely. For millions of patients and healthcare providers, this isn’t a hypothetical scenario-it’s the daily reality of the drug shortage crisis. When essential medicines vanish from shelves, the ripple effects are immediate and severe: treatments get delayed, surgeries get cancelled, and patients face higher risks of adverse health outcomes. This article breaks down exactly how these shortages impact patient care, why they happen, and what the data says about their human and economic cost.

The Scale of the Crisis: More Than Just Empty Shelves

To understand the impact, you first need to grasp the scale. Drug shortages aren’t new-they date back to World War II-but the current situation is unprecedented. According to the American Society of Health-System Pharmacists (ASHP), which has tracked these issues since 2001, we hit an all-time high of 323 active drug shortages in the first quarter of 2024. While that number dipped slightly to 253 by June 2025, it remains far above the 187 shortages recorded in 2021. What makes this period particularly acute is that 72% of these ongoing shortages began in 2022 or later. This isn’t a temporary glitch; it’s a structural failure affecting hundreds of medications simultaneously.

The types of drugs affected matter immensely. It’s not usually the latest blockbuster cancer pill that goes missing. Instead, the crisis hits generic drugs hardest, comprising up to 83% of all shortages. These are the low-margin workhorses of medicine: IV saline bags, heparin, antimicrobials, and anesthesia agents. Because there are often only one or two manufacturers for these specific generics, if one factory has a quality issue or shuts down, the entire supply chain snaps. The result? A fractured global supply chain responsible for 47% of shortages, followed closely by manufacturing quality issues at 32%.

Clinical Consequences: Errors, Delays, and Disrupted Care

When a drug isn’t available, doctors don’t just shrug and move on. They have to pivot, and those pivots carry risk. The most direct impact on patient care is the increase in medication errors. The National Institutes of Health (NIH) analysis shows a stark 43% increase in medication errors directly attributable to shortages, up from 38% in 2019. Why does this happen? When pharmacists and nurses switch to alternative therapies-often ones they aren’t as familiar with-the margin for error widens. Dosing calculations change, administration routes might differ, and monitoring requirements shift. During transition periods, error rates can spike by over 18%.

Beyond errors, there’s the sheer disruption to planned care. NIH data indicates a 32% disruption rate in planned medical procedures due to missing drugs. In cardiac surgery centers, for example, shortages of heparin forced teams to develop alternative anticoagulation protocols. This didn’t just mean swapping pills; it increased procedure times by 22%, keeping patients under anesthesia longer and raising the risk of complications. For oncology patients, the stakes are even higher. Shortages of critical drugs like asparaginase for acute lymphoblastic leukemia have caused treatment delays of 7 to 14 days. In cancer care, time is tissue; every day of delay can affect survival rates.

The Human Cost: Stress, Dissatisfaction, and Access Barriers

Behind the statistics are real people experiencing frustration and fear. The humanistic impact of drug shortages is profound. Patients report feeling anxious when their trusted medication is replaced by an unfamiliar alternative. A study published in the Journal of Managed Care & Specialty Pharmacy found that 38% of respondents reported patient complaints during shortage periods. This dissatisfaction stems from a loss of continuity. For chronic conditions like pain management or mental health disorders, consistency is key. Shortages of oral opioids or lorazepam injections force patients to navigate complex prior authorizations or travel to multiple pharmacies just to fill a prescription.

Financial strain adds another layer of stress. When preferred generic drugs are unavailable, patients are often switched to brand-name alternatives or other generics that may not be covered equally by insurance. The NIH notes that patients experience an average 18.7% increase in out-of-pocket costs during shortage periods. For many, this leads to rationing. Nearly 30% of Americans admit to not taking medication as prescribed due to cost, a figure exacerbated by shortages. The American Hospital Association estimates that 1.1 million Medicare patients could die over the next decade because they cannot afford or access prescribed medications-a grim projection tied directly to access barriers worsened by supply instability.

Economic Burden on Healthcare Systems

If you think the cost is just about the price of the pill, think again. The economic burden falls heavily on hospitals and healthcare systems. Vizient’s 2024 survey of 132 facilities reveals that drug shortages cost hospitals nearly $900 million annually in additional labor expenses alone. That doesn’t include the cost of alternative therapies, cancelled surgeries, or potential liability from medication errors.

Where does this money go? It goes into administrative chaos. Hospitals spend an average of 15 to 20 labor hours per week per shortage just to monitor availability, source alternatives, and update protocols. Pediatric facilities face an even heavier burden, requiring 25% more staff time due to the complexity of pediatric formulations. Pharmacists are spending less time counseling patients and more time playing detective, calling distributors across the country to find a single vial of insulin or saline. This staffing surge drains resources from other critical areas, creating a cycle of burnout and inefficiency that further degrades care quality.

Why Are Shortages Happening Now?

The root causes are systemic, not accidental. The primary driver is the lack of financial incentive to produce low-margin generic drugs. With only one or two manufacturers for many essential medicines, competition is minimal. If a manufacturer faces a raw material shortage-which accounts for 21% of shortages-they can simply raise prices or reduce output without losing market share to competitors. This oligopoly structure creates fragility.

Furthermore, the global nature of pharmaceutical supply chains means a disruption anywhere can cause a blackout everywhere. Raw materials for active pharmaceutical ingredients (APIs) often come from a limited number of countries. Geopolitical tensions, natural disasters, or pandemic-related lockdowns can sever these links instantly. While the FDA implemented new reporting requirements under the Drug Shortage Electronic Registration and Notification Act of 2022-requiring manufacturers to notify them six months before potential shortages-the system still struggles with demand-driven shortages that arise suddenly from distribution bottlenecks rather than production halts.

What Can Be Done? Mitigation and Future Outlook

Healthcare systems are fighting back, but solutions are evolving slowly. Group purchasing organizations (GPOs) like Vizient have become vital partners, generating nearly $300 million in inventory cost avoidance for clients since 2023 by pooling demand and securing better supply contracts. However, individual hospitals are also building resilience. By 2027, 78% of hospital systems plan to increase onshoring of critical medications, aiming to bring production closer to home to reduce reliance on volatile international supply chains.

For patients and providers, the immediate strategy involves vigilance and communication. Therapeutic substitution committees within hospitals help standardize alternatives to minimize errors. Automated monitoring systems alert pharmacists early when supplies run low. Yet, as the JAMA Network Open analysis warns, public health surveillance needs upgrading to capture the full frequency of demand-driven issues. Until then, the focus remains on mitigation: preserving continuity of care, preventing errors, and safeguarding vulnerable populations who rely on these life-saving medications.